{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:01:30Z","timestamp":1784811690932,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["04151266"],"award-info":[{"award-number":["04151266"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["05162326"],"award-info":[{"award-number":["05162326"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncolytics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.omto.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T20:17:15Z","timestamp":1581106635000},"page":"302-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination"],"prefix":"10.1016","volume":"16","author":[{"given":"Zhiwu","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sum","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Wing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yik Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haode","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2020.01.009_bib1","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2020.01.009_bib2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"Baldini","year":"2015","journal-title":"J.\u00a0Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.omto.2020.01.009_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2020.01.009_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JOP.2016.016576","article-title":"The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma","volume":"12","author":"Kindler","year":"2016","journal-title":"J.\u00a0Oncol. Pract."},{"key":"10.1016\/j.omto.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/imt-2016-0123","article-title":"Anti-CTLA-4 therapy for malignant mesothelioma","volume":"9","author":"Guazzelli","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.omto.2020.01.009_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2020.01.009_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/14737140.2016.1162100","article-title":"A catalogue of treatment and technologies for malignant pleural mesothelioma","volume":"16","author":"Schunselaar","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.omto.2020.01.009_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T\u00a0cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.omto.2020.01.009_bib11","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1158\/0008-5472.CAN-14-0473","article-title":"Vaccine-elicited CD8+ T\u00a0cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment","volume":"74","author":"Tan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2020.01.009_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omto.2020.01.009_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.01.009_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.omto.2020.01.009_bib16","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/j.jtho.2016.11.304","article-title":"Autologous Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (Pheralys (R)) in Patients with Mesothelioma: Final Results of a Phase I Study","volume":"12","author":"Aerts","year":"2017","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.omto.2020.01.009_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial-mesenchymal transition in malignant mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.omto.2020.01.009_bib18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2020.01.009_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reyni\u00e8s","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjc.6602876","article-title":"A twist for survival and cancer progression","volume":"94","author":"Puisieux","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2020.01.009_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccr.2008.06.005","article-title":"Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence","volume":"14","author":"Ansieau","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2020.01.009_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","article-title":"Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis","volume":"117","author":"Yang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.omto.2020.01.009_bib23","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1158\/0008-5472.CAN-12-1033","article-title":"TWIST1 is an ERK1\/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells","volume":"72","author":"Weiss","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2353\/ajpath.2009.080721","article-title":"Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis","volume":"174","author":"Romagnoli","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"Suppl.","key":"10.1016\/j.omto.2020.01.009_bib25","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1538-7445.AM2012-3404","article-title":"Exploring the role of Twist1 in the pathogenesis of malignant pleural mesothelioma (MPM)","volume":"72","author":"Suraokar","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib26","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/0008-5472.CAN-13-2045","article-title":"Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process","volume":"74","author":"Ardiani","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib27","doi-asserted-by":"crossref","first-page":"90825","DOI":"10.18632\/oncotarget.19967","article-title":"Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer","volume":"8","author":"Malamas","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2020.01.009_bib28","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI64704","article-title":"PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T\u00a0cells in mice","volume":"123","author":"Zhou","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2020.01.009_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T\u00a0cells and natural killer T\u00a0cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.omto.2020.01.009_bib30","doi-asserted-by":"crossref","first-page":"32426","DOI":"10.18632\/oncotarget.5856","article-title":"Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2020.01.009_bib31","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI93303","article-title":"Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy","volume":"128","author":"Hailemichael","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2020.01.009_bib32","doi-asserted-by":"crossref","first-page":"e1518672","DOI":"10.1080\/2162402X.2018.1518672","article-title":"Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression","volume":"8","author":"Tan","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2020.01.009_bib33","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","article-title":"TGF\u03b2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity","volume":"75","author":"Vanpouille-Box","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib34","doi-asserted-by":"crossref","first-page":"28194","DOI":"10.18632\/oncotarget.4442","article-title":"A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model","volume":"6","author":"Kwilas","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2020.01.009_bib35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.183.3.725","article-title":"Human tumor antigens recognized by T lymphocytes","volume":"183","author":"Boon","year":"1996","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2020.01.009_bib36","doi-asserted-by":"crossref","first-page":"e1433516","DOI":"10.1080\/2162402X.2018.1433516","article-title":"Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T\u00a0cell epitopes with a human IgG1 antibody induces potent T\u00a0cell responses that are associated with favourable clinical outcome in a phase I\/II trial","volume":"7","author":"Patel","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2020.01.009_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omto.2020.01.009_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/cr.2011.144","article-title":"Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms","volume":"22","author":"Qin","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.omto.2020.01.009_bib39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.omto.2020.01.009_bib40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omto.2020.01.009_bib41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2020.01.009_bib42","doi-asserted-by":"crossref","first-page":"e1376154","DOI":"10.1080\/2162402X.2017.1376154","article-title":"Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T\u00a0cell infiltrate and eradicates tumors in an orthotopic glioma model","volume":"7","author":"Field","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2020.01.009_bib43","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.01.009_bib44","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","article-title":"Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.01.009_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-62703-008-3_17","article-title":"Mouse models for tumor metastasis","volume":"928","author":"Yang","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omto.2020.01.009_bib46","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in\u00a0vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."}],"container-title":["Molecular Therapy Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237277052030019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237277052030019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:11:52Z","timestamp":1784808712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S237277052030019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":46,"alternative-id":["S237277052030019X"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2020.01.009","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}